NewEdge Advisors LLC Lowers Holdings in Globus Medical, Inc. $GMED

NewEdge Advisors LLC trimmed its position in Globus Medical, Inc. (NYSE:GMED) by 66.9% in the 1st quarter, Holdings Channel reports. The firm owned 8,426 shares of the medical device company’s stock after selling 17,023 shares during the quarter. NewEdge Advisors LLC’s holdings in Globus Medical were worth $726,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in GMED. SBI Securities Co. Ltd. increased its holdings in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the period. Advisory Services Network LLC purchased a new stake in shares of Globus Medical in the third quarter worth $26,000. EverSource Wealth Advisors LLC boosted its stake in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. Larson Financial Group LLC boosted its stake in Globus Medical by 83.4% during the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after buying an additional 242 shares during the period. Finally, Summit Securities Group LLC purchased a new position in Globus Medical during the first quarter worth about $48,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 18.38% of the company’s stock.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $78.99 on Monday. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The firm has a fifty day moving average of $79.53 and a 200 day moving average of $85.57. The firm has a market capitalization of $10.72 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.95.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. During the same quarter last year, the business posted $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Needham & Company LLC upped their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. UBS Group started coverage on Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. Finally, Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.